Shyam A. Patel, MD, PhD, discusses the threshold of p53 IHC positivity best correlating with multi-hit TP53 mutational status in MDS and AML.
Shyam A. Patel, MD, PhD
Advertisement
Shyam A. Patel, MD, PhD, is an associate professor at the University of Massachusetts Chan Medical School; as well as a hematologist and oncologist at the UMass Memorial Medical Center.
Articles by Shyam A. Patel, MD, PhD
Drs Gerber and Patel discuss a study they conducted investigating the use of IHC as a biomarker for early TP53 mutation identification in MDS and AML.
Shyam A. Patel, MD, PhD, discusses secondary prevention strategies that may mitigate the risk of developing SPCs after receipt of CAR T-cell therapy.
Drs Dahiya and Patel discuss how SPC research may help optimize CAR T-cell product development in the future.
Shyam A. Patel, MD, PhD, discusses the impact of donor-engrafted clonal hematopoiesis on the risk of disease relapse and survival outcomes with allo- and auto-HSCT.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ST-001 nanoFenretinide Shows Antitumor Activity in Previously Treated Cutaneous T-Cell Lymphoma
2
Immune and Single-Cell Profiling Reveals Drivers of Mogamulizumab Resistance in Mycosis Fungoides and Sézary Syndrome
3
Dibotatug Is Safe and Shows Activity in R/R Cytotoxic T/NK Cell Lymphomas
4
Pegylated Interferon Alfa-2a Is Safe and Tolerable in Real-World CTCL Study
5